Monday, December 18, 2017

DaVita pharmacy unit settles billing fraud case for $63.7M

Becker's Hospital Review-4 hours ago
Coppell, Texas-based DaVita Rx, a pharmacy services unit of Denver-based DaVita, will pay $63.7 million to resolve False Claims Act allegations, according to the Department of Justice. The settlement resolves allegations that DaVita Rx billed government payers for prescription medications that were never shipped, that ...

FDA proposes new, risk-based enforcement priorities to protect consumers from potentially harmful, unproven homeopathic drugs

FDA continues to find that some homeopathic drugs are manufactured with active ingredients that can create health risks while delivering no proven medical benefits
Today, the U.S. Food and Drug Administration proposed a new, risk-based enforcement approach to drug products labeled as homeopathic. To protect consumers who choose to use homeopathic products, this proposed new approach would update the FDA’s existing policy to better address situations where homeopathic treatments are being marketed for serious diseases and/or conditions but where the products have not been shown to offer clinical benefits. It also covers situations where products labeled as homeopathic contain potentially harmful ingredients or do not meet current good manufacturing practices. Continue reading.